The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research, part of the U.S. National Institutes of Health, along with the Indian Institute of Technology Bombay (IITB) and Tata Memorial Centre (TMC) have signed a Memorandum of Understanding (MOU) on clinical proteogenomics cancer research.
The MOU between NCI, IITB, and Tata Memorial Centre represents the thirtieth and thirty-first institutions and the twelfth country to join the International Cancer Proteogenome Consortium (ICPC).
The scope of the collaboration requires NCI to assist IITB and TMC in adopting and implementing the Clinical Proteomic Tumour Analysis Consortium workflows as appropriate and to integrate innovative technologies in workflows based on commonly diagnosed cancers in India.
The MOU intends to enhance the understanding of proteogenomic complexity of tumours, facilitate the identification of treatments to use against a specific patient’s tumour, and develop targeted multiplexed proteomic assays that consider population variation.
Cooperation under this MOU is intended to leverage and maximize each entity’s mission, current infrastructure, and research programs that advance the understanding of cancer and its treatment.